Does someone you love have Fragile X syndrome (FXS)?
If so, please know that we are currently enrolling individuals with FXS between 15 and 55 years of age to participate in a medical research study.
In this research study, we will evaluate the effects of the investigational drug Metadoxine Extended Release (MDX) on the symptoms of ADHD in individuals with Fragile X.
There is no cost to participate in our research study, and compensation for time and travel may be available.
To learn more about our research study, please contact:
Libby Bliss, Research Manager
Seattle Children’s Child Psychiatry and Behavioral Medicine
Principle Investigator – Mark Stein, PhD
(Western IRB) IRB# 12270005.0